Eli Lilly and Company (Lilly) has announced its updated revenue guidance for 2025, as well as new information on its 2024 results. According to the company, it now expects worldwide revenue to be approximately $40.7 billion in 2024, with sales of Mounjaro and Zepbound posting robust growth.
For 2025, Lilly anticipates revenue growth contributions from new medicines such as Jaypirca, Ebglyss, Omvoh, and Kisunla, as well as approvals of new indications for existing medicines. The company also expects to launch Mounjaro in additional worldwide markets and potentially launch new medicines like imlunestrant for metastatic breast cancer.
Lilly’s 2025 revenue guidance range is estimated at $42.8 billion to $44.6 billion, with the company expecting to produce at least 60% more salable doses of incretins in the first half of 2025 compared to the same period last year.
The company also plans to share its full Q4 2024 financial results and 2025 financial guidance on March 11, 2024. Preliminary information released by Lilly may vary materially from final results due to various factors, including financial closing procedures and other developments.
Lilly is a medicine company focused on harnessing the power of biotechnology, chemistry, and genetic medicine to solve some of the world’s most significant health challenges. The company has been pioneering life-changing discoveries for nearly 150 years and aims to make life better for millions more people.
Source: https://investor.lilly.com/news-releases/news-release-details/lilly-provides-update-2024-revenue-guidance-announces-2025